Project Grant R35GM165539
- The National Institute of General Medical Sciences awarded the University of Florida $1,892,969 on September 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop novel mass spectrometry technologies for high-resolution molecular imaging of tissue samples. The research addresses critical deficiencies in imaging mass spectrometry (IMS) by advancing chemistries and next-generation analytical techniques that improve both chemical differentiation and spatial...
- The National Institute of General Medical Sciences awarded the University of Florida $386,985 on July 23, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to conduct a five-year investigation into the structure-function relationships of single-stranded DNA (ssDNA) in biological systems. The research will develop methods to probe structured ssDNA in cells, with initial focus on two biomedically relevant lines of investigation. The first examines complex ssDNA...
- The National Institute of General Medical Sciences awarded the University of Washington $2,102,360 on May 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop ultrahigh multiplexing fluorescent probes and methods for spatial transcriptomics of tissue samples. The funded work encompasses design, synthesis, and characterization of over 1,000 spectrally and DNA-barcoded fluorescent probes conjugated with DNA oligonucleotide barcodes to enable single-molecule...
- The National Institute of General Medical Sciences awarded Third Floor Materials, Inc. (3FM) $298,111 on September 2, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop a high-throughput snapshot hyperspectral imager for multiplexed fluorescence microscopy. The system combines proprietary plasmonic filter arrays with backside-illuminated CMOS sensors to enable capture of complete hyperspectral datacubes—containing both spectral and spatial...
- The National Institute of General Medical Sciences awarded the University of Florida $322,252 on August 5, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to discover and characterize small molecule inhibitors of bacterial ribonuclease P (RNase P), a tRNA processing enzyme. Work is performed in Gainesville, Florida through April 30, 2030. The project integrates structural biology, biochemistry, and computation to develop small molecule inhibitors targeting RNase...
- Federal Grant Award Summary The National Institute of General Medical Sciences (NIGMS) awarded University of California, Irvine a $1.89 million Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) effective September 1, 2025, through August 31, 2029. The research initiative focuses on developing molecular lanterns—ultra-small ribonucleic acid (RNA) tags that assemble split luciferases—to enable real-time visualization and tracking of multiple RNA transcripts...
- The National Institute of General Medical Sciences awarded Molecular Instruments, Inc. $306,788 on September 30, 2025, under the Biomedical Research and Research Training program (CFDA 93.859) to advance probe technology for ultrasensitive RNA imaging via hybridization chain reaction (HCR). The project develops and refines in situ amplification methods based on HCR mechanism to overcome multi-decade limitations in RNA fluorescence in situ hybridization (RNA-FISH). Specifically, the work...
- The National Institute of General Medical Sciences awarded the University of South Florida $474,102 on June 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to conduct synthetic biology and genome engineering of polyketide natural products, develop bioactive metabolites from Antarctic marine invertebrates and deep-sea organisms, synthesize chemical analogs to modulate toxicity and enhance drug-like properties, and advance compound development initiatives...
- The National Institute of General Medical Sciences awarded $764,052 to the Trustees of Indiana University on September 15, 2025, under the Biomedical Research and Research Training program (CFDA 93.859) to synthesize, characterize, and implement a palette of target-specific organic dyes with biologically-responsive long-lived fluorescence lifetimes, primarily incorporating thermally activated delayed fluorescence (TADF) photophysics for use in fluorescence lifetime imaging microscopy (FLIM)...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded the University of Florida $454,738 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how cytosolic pattern recognition receptors sense membrane-replicating positive-strand RNA viruses despite viral replication sequestering viral RNA from host cell cytoplasmic sensors. The research addresses a fundamental paradox in...
The National Institute of General Medical Sciences, National Institutes of Health, awarded the University of Florida $422,125 on August 15, 2026, to develop rapid, wash-free fluorescent signal-switching methods for high-plex RNA imaging in cells and tissues under the Biomedical Research and Research Training program (CFDA 93.859). The research addresses limitations in current multiplexed fluorescence imaging by establishing a DNA displacement reaction-based signal exchange (DIRSE) platform that enables theoretically unlimited rapid multiplexed RNA imaging with no additional accessories. Each round of signal exchange occurs within 30 seconds, compared to tens of minutes to hours required by existing fluidic-exchange sequential DNA imaging approaches. The work includes developing 60 different toehold probes with rapid kinetics and enabling high-plex imaging in three-dimensional tissue samples, which currently require days of incubation time with conventional methods. The project runs through April 30, 2031, with work performed in Gainesville, Florida.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $422.1k | 8/5/26 |